Antiretroviral chemotherapy

Current Clinical Topics in Infectious Diseases

Volumn , Issue 18, 1998, Pages 154-179

  Saag, Michael S ^a   Schooley, Robert T ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ABACAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; OXAZINE DERIVATIVE; RITONAVIR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

DRUG EFFECT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; REVIEW;

ANTI-HIV AGENTS; DELAVIRDINE; DIDANOSINE; DIDEOXYNUCLEOSIDES; HIV INFECTIONS; HIV-1; HUMANS; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; OXAZINES; RITONAVIR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

EID: 0031615751     PISSN: 01953842     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (77)

1. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117-122.
2. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373: 123-126.
3. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996;217: 1582-1586.
4. Finzi D, Hermankova M, Siliciano RF, et al. Identification of a reservoir for HIV-1 patients on highly active antiretroviral therapy. Science 1997;278:1295-1300.
5. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997;387: 188-191.
6. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995;267:483-489.
7. Carptenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society-USA Panel. JAMA 1997;277:1962-1969.
8. Report of the NIH Panel to Define Principles of Therapy of HIV Infection (draft). 1997: 1-36.
9. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebocontrolled trial. N Engl J Med 1987;317:185-191.
10. Piatak M, Saag M, Yang L, et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 1993;259:1749-1754.
11. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in patients with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med 1990; 322:941-949.
12. Concorde Coordinating Committee. Concorde: MRC/ANRS randomized double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994;343:871-881.
13. Hamilton JD, Hartigan PM, Simberkoff MS, et al. A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. N Engl J Med 1992;326:437.
14. Katzenstein DA, Hammer SM, Hughes MD, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1996;335:1091-1098.
15. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-733.
16. Gullick RM, Mellors J, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-739.
17. Richman DD, Fischl MA, Grieco MH, et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebocontrolled trial. N Engl J Med 1987;317:192-197.
18. Saag MS. Nucleoside analogues: adverse effects. Hosp Pract 1992;27(Suppl 2):26-36.
19. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989; 243:1731-1734.
20. Kuritzkes DR. Clinical significance of drug resistance in HIV-1 infection. AIDS 1996; 10(Suppl 5):S27-S31.
21. Holodniy M, Mole L, Margolis D, et al. Determination of human immunodeficiency virus RNA in plasma and cellular viral DNA genotypic zidovudine resistance and viral load during zidovudine-didanosine combination therapy. J Virol 1995;69:3510-3516.
22. Connor EM, Sperling RS, Gelber R, et al, for the Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994;331: 1173-1180.
23. Sperling RS, Shapiro DE, Coombs RW, et al, for the Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med 1996;335:1621-1629.
24. Report of the NIH Panel to Define Guidelines of Therapy of HIV Infection. MMWR 1998 (in press).
25. Centers for Disease Control and Prevention. AIDS among children-United States, 1996. MMWR 1996;45:1006-1010.
26. Centers for Disease Control and Prevention. Case-control study of HIV seroconversion in health-care workers after percutaneous exposure to HIV-infected blood - France, United Kingdom, and United States, January 1988-August 1994. MMWR 1995;44:929-933.
27. Bell DM. Occupational risk of human immunodeficiency virus infection in healthcare workers: an overview. Am J Med 1997; 102:9-15.
28. Centers for Disease Control and Prevention. Update: provisional recommendations for chemoprophylaxis after occupational exposure to human immunodeficiency virus. MMWR 1996;45:468-472.
29. Saag MS. Candidate antiretroviral agents for use in postexposure prophylaxis. Am J Med 1997;102:25-31.
30. Kahn JO, Lagakos SW, Richman DD, et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med 1992;327:581-587.
31. Hammer SM, Katzentstein DA, Hughes MD, et al, for the AIDS Clinical Trials Group Study 175 Study Team. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500/μL. N Engl J Med 1996;335:1081-1090.
32. Dolin R, Amato DA, Fischl MA, et al. Zidovudine compared with didanosine in patients with advanced HIV type 1 infection and little or no previous experience with zidovudine. AIDS Clinical Trials Group. Arch Intern Med 1995; 155:961-974.
33. Winters MA, Shafer RW, Jellinger RA, Mamtora G, Gingeras T, Merigan TC. Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years. Antimicrob Ag Chemother 1997;41:757-762.
34. Shafer RW, Winters MA, Merigan TC. Multiple concurrent RT and protease mutations and multidrug resistance in heavily treated HIV-1 infected patients. In: Programs and abstracts of the 6th International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication. June 25-28, 1997, St. Petersburg, FL. Abstract 39.
35. Yarchoan R, Pluda JM, Thomas RV, et al. Long-term toxicity/activity profile of 2′,3′-dideoxyinosine in AIDS or AIDS-related complex. Lancet 1990;336:526-529.
36. Merigan TC, Skowron G, Bozzette SA, et al. Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections. A phase I and II study. Ann Intern Med 1989;110:189-194.
37. Delta Coordinating Committee. Delta: a randomized double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996;343:283-291.
38. Murray HW, Squires KE, Weiss W, et al. Stavudine in patients with AIDS and AIDS-related complex: AIDS Clinical Trials Group 089. J Inf Dis 1995;171(Suppl 2):S123-S130.
39. 4T or AZT/3TC. In: Program and abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections. January 22-27, 1997, Washington, DC. Abstract 370.
40. Spruance W, Pavia AT, Mellors JW, et al. Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. A randomized, double-blind, controlled trial. Bristol-Myers Squibb Stavudine/019 Study Group. Ann Intern Med 1997;126:355-363.
41. 4/3TC antiretroviral naive and experienced patients. In: Program and abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections. January 22-27, 1997, Washington, DC. Abstract LB4.
42. 4T) and didanosine (ddl) combination therapy in HIV-infected subjects in an ongoing pilot randomized double-blind trial. In: Program and abstracts of the Third Conference on Retroviruses and Opportunistic Infections. January 28-February 1, 1996, Washington, DC. Abstract 197.
43. Eron JJ, Benoit SL, Jemsek J, MacArthur RD. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N Engl J Med 1995;333:1662-1669.
44. Staszewski S, Bartlett J, Hill AM, Katlama C, Johnson J. Reductions in HIV-1 disease progression for zidovudine/lamivudine relative to control treatments: a meta-analysis of controlled trials. AIDS 1997;11:474-483.
45. Van Leeuwen R, Katlama C, Kitchen V, et al. Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study. J Infect Dis 1995;171:1166-1171.
46. D'Aquila RT. HIV-1 chemotherapy and drug resistance. Clin Diagn Virol 1995;3:299-316.
47. 3. In: Programs and abstracts of the 11th International Conference on AIDS. July 1996, Vancouver, Canada. Abstract 2675.
48. Merluzzi VJ, Hargrave KD, Labadia M, et al. Inhibition in HIV-1 replication by a non-nucleoside RT inhibitor. Science 1990;250: 1411-1413.
49. Merluzzi VJ, Hargrave KD, Labadia M, et al. Inhibition in HIV-1 replication by a non-nucleoside RT inhibitor. Science 1990;250: 1411-1413.
50. Havlir D, Cheeseman SH, McLaughlin M, et al. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 1995;171:537-545.
51. Richman DD, Havlir D, Corbeil J. Nevirapine resistance mutations of human immunodeficiency virus type-1 selected during therapy. J Virol 1994;63:1660-1668.
52. 3. AIDS Clinical Trials Group Protocol 208. J Infect Dis 1995;172:1379-1383.
53. 3). In: Program and abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections. 1997, Washington, DC. Abstract LB6.
54. D'Aquila RT, Hughes MD, Johnson VA, et al. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. Ann Intern Med 1996;124:1019-1030.
55. Freimuth WW, Wong Y, Docci S, et al. Surrogate marker responses from an open-label extended use of delavirdine mesylate (DLV) treatment of triple combination (ZVD + DLV + DDI, or ZVD + DLV + DDC) for HIV-1 patients. Presented at the Tenth International Conference on AIDS. July 7-11, 1996, Vancouver, Canada. Abstract MOB 1134.
56. Fiske WD, Benedek LH, White SJ, Joseph JL, Kernhauser DM. Pharmacokinetic interaction between DMP 266 and nelvinavir mesylate (NFV) in healthy volunteers. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. September 1997, San Francisco, CA. Abstract 1-174.
57. Fiske WD, Mayers D, Wagner K, et al. Pharmacokinetics of DMP 266 and indinavir multiple oral doses in HIV-1 infected individuals. In: Program and abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections. 1997, Washington, DC. Abstract 568.
58. Mayers D, Riddler S, Bach M, et al. Durable clinical anti-HIV-1 activity and tolerability for DMP 266 in combination with indinavir (IDV) at 24 weeks. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. September 1997, San Francisco, CA. Abstract I-175.
59. Bacheler LT, George H, Abremski K, et al. Mutations associated with viral load rebound in patients treated with the HIV-1 non-nucleoside reverse transcriptase inhibitor DMP 266 in combination with the HIV-1 protease inhibitor crixivan. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. September 1997, San Francisco, CA. Abstract I-172.
60. Ruiz N, DuPont Merck Study Group. A double-blind pilot study to evaluate the antiretroviral activity, tolerability of DMP 266 in combination with indinavir (Cohort III). In: Program and abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections. 1997, Washington, DC. Abstract LB2.
61. Decks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors. A review for clinicians. JAMA 1997;277:145-153.
62. Kitchen VS, Skinner C, Ariyoshi K, et al. Safety and activity of saquinavir in HIV infection. Lancet 1995;345:952-955.
63. Collier AC, Coombs R, Schoenfeld DA, et al. Treatment for human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996;334:1011-1017.
64. Vella S. Clinical experience with saquinavir. AIDS 1996;9:21-25.
65. 3) in patients discontinuing or unable to take retrovir. Executive summary-clinical endpoint analysis. May 3, 1996.
66. Cohen C, Sun E, Cameron W, et al. Ritonavir-saquinavir combination treatment in HIV-infected patients. In: Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. September 15-18, 1996, New Orleans, LA. Abstract LB7b.
67. Jacobsen H, Hanggi M, Ott M, et al. In vivo resistance to an HIV-1 proteinase inhibitor: mutations, kinetics and frequencies. J Infect Dis 1996;173:1379-1387.
68. Condra JH, Schleif WA, Blahy OM, et al. In vivo emergency of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995; 374:569-571.
69. Molla A, Komeyeva M, Gao Q, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med 1996;2: 760-766.
70. Markowitz M, Saag M, Powderly WG, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995;333:1534-1539.
71. Danner SA, Carr A, Leonard JM, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995;333:1528-1533.
72. Cameron B, Heath-Chiozzi M, Kravcik S, et al. Prolongation of life and prevention of AIDS in advanced HIV immunodeficiency with ritonavir. In: Program and abstracts of the Third Conference on Retroviruses and Opportunistic Infections. January 28-February 1, 1996, Washington, DC. Abstract LB6a.
73. Heath-Chiozzi M, Leonard J, Henry D, et al. Anti-HIV activity and lymphocyte surrogate marker response dynamics to ritonavir therapy in advanced HIV immunodeficiency. In: Program and abstracts of the Third Conference on Retrovirnses and Opportunistic Infections. January 28-February 1, 1996, Washington, DC. Abstract LB6b.
74. Feinberg M. Hidden dangers of incompletely suppressive antiretroviral therapy. Lancet 1997; 349:1408-1409.
75. Saag M, Knonles M, Chang Y, Yu G, Chapman S, Clendeninn NJ. Durable effect of viracept (nelfinavir mesylate, NFV) in triple combination therapy. In: Programs and abstracts of the 37th International Conference on Antimicrobial Agents and Chemotherapy. September 1997, Toronto, Canada.
76. Havlir D, Richman DD. Viral dynamics of HIV: implications for drug development and therapeutic strategies. Ann Intern Med 1996; 124:984-994.
77. Saag MS, Holodniy M, Kuritzkes DR, et al. HIV viral load markers in clinical practice: recommendations of an International AIDS Society - USA Expert Panel. Nat Med 1996; 2:625-629.